Search Results
Your search for ,had matches 18600 pages
Showing 7901 - 7950Treating Typical Solitary Fibrous Tumor With a Tyrosine Kinase Inhibitor
In a European phase II trial reported in The Lancet Oncology, Martin-Broto et al found that pazopanib showed activity in patients with typical solitary fibrous tumors. The investigators previously reported findings with pazopanib treatment in a cohort of patients in the trial with advanced...
Updates in Hematopoietic Cell Transplantation
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on allogeneic and autologous hematopoietic cell transplantation. For full...
Update on Project Facilitate at the Oncology Center of Excellence
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Mitchell Chan, PharmD, BCPS, Regulatory Project Manager; Tamy Kim, PharmD, Associate Director of Regulatory ...
Expert Point of View: Kevin Kalinsky, MD, MS
Commenting on SAFIR02-IMMUNO for The ASCO Post, Kevin Kalinsky, MD, MS, Associate Professor of Medicine at NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, said the findings of the analysis were in accordance with other studies in metastatic breast cancer, but they came...
Mixed Results With Durvalumab Maintenance in HER2-Negative Advanced Breast Cancer
Given as maintenance therapy, the checkpoint inhibitor durvalumab significantly improved overall survival in patients with metastatic triple-negative breast cancer and yielded a numerical but not significant benefit as well for patients expressing programmed cell death ligand 1 (PD-L1), in...
Cancer in the Aging Population: ‘Leaving No One Behind’
With the motto of “leaving no one behind,” 420 delegates from 40 countries and 61 faculty members from 19 countries attended the Annual Meeting of the International Society of Geriatric Oncology (SIOG) in Geneva on November 14–16, 2019. SIOG serves as a platform to discuss a myriad of aspects...
Use of Cell-Free DNA Methylation–Based Blood Test in Detecting Gastrointestinal Cancers
A noninvasive, blood-based, cell-free DNA test focused on the presence of DNA methylation appears to be highly sensitive in detecting gastrointestinal cancers and may pinpoint the tissue of origin in the vast majority of these cancers.1 The assay was developed based on findings from the...
Value: Is the Benefit Worth the Cost?
AS A YOUNG CLINICIAN, I was interested in making a difference; it did not matter how much of a difference, as long as I could claim some patient benefit. And I really didn’t care what benefit: better survival, less local recurrence, shorter hospital stays, fewer narcotics—the specifics did not...
Redefining What It Means to Have Precursor Myeloma
Studies have shown that all patients diagnosed with multiple myeloma had a preceding asymptomatic expansion of clonal plasma cells, clinically recognized as monoclonal gammopathy of undetermined significance or smoldering multiple myeloma. According to C. Ola Landgren, MD, PhD, Professor of...
Patient-Reported Outcomes From IMbrave150: Better Quality of Life With Doublet
For the first-line treatment of advanced hepatocellular carcinoma, atezolizumab plus bevacizumab provided a significant overall survival benefit in the pivotal IMbrave150 trial. New findings from a prespecified analysis also showed numerous benefits for the doublet in terms of quality of life,...
Venetoclax Plus Dexamethasone Shows Activity in t(11;14) Multiple Myeloma
In a phase I/II study of patients with advanced multiple myeloma and t(11;14) translocations, the combination of venetoclax and dexamethasone showed strong, durable activity, even in patients refractory to daratumumab, study investigators reported at the 2019 American Society of Hematology (ASH)...
Immunogenomic Profiling of Osteosarcoma
Comprehensive profiling of tumor samples taken from patients with osteosarcoma showed that multiple factors contribute to the traditionally poor responses observed with immune checkpoint inhibitor treatment in patients with this malignancy, according to new research published by Wu et al in Nature...
Hippocampal Avoidance During Whole-Brain Radiotherapy: Effects on Cognitive Function
As reported in the Journal of Clinical Oncology by Brown et al, the phase III NRG Oncology CC001 trial has shown superior cognitive function outcomes with hippocampal avoidance using intensity-modulated radiotherapy during whole-brain radiotherapy (WBRT) for the treatment of adult patients with...
Addition of Capivasertib to Fulvestrant in Advanced ER-Positive Breast Cancer After Relapse or Disease Progression With Aromatase Inhibitor Treatment
In the phase II FAKTION trial reported in The Lancet Oncology, Jones et al found that the addition of the AKT inhibitor capivasertib to endocrine therapy with fulvestrant prolonged progression-free survival in postmenopausal women with aromatase inhibitor–resistant, estrogen receptor (ER)-positive, ...
Late Mortality and Chronic Health Conditions in Long-Term Survivors of AYA Cancers
A retrospective analysis from the Childhood Cancer Survivor Study, reported in The Lancet Oncology by Eugene Suh, MD, and colleagues, showed that as with survivors of childhood cancers, survivors of adolescent and young adult (AYA) cancers are at increased risk of earlier mortality and chronic...
Using Antioxidants and Other Supplements With Chemotherapy May Increase Risk of Breast Cancer Recurrence and Mortality
Using antioxidants and other dietary supplements before and during adjuvant chemotherapy for breast cancer may increase the risk of recurrence and “to a lesser extent, death,” according to an analysis of dietary and nutritional data from a phase III trial, published in the Journal of Clinical...
Cancer Has Made Me the Person I Am, and I’m Grateful
The only clue that I was harboring a life-threatening cancer came as I was driving to a golf lesson in the fall of 2006, and I casually rubbed the left side of neck and felt a tiny bump. Although I wasn’t alarmed at the time, I did point out the mass to my primary care physician when I met with...
FDA Pipeline: Priority Reviews in Lung Cancers, Lymphoma
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for non–small cell and small cell lung cancers, as well as for diffuse large-B cell lymphoma (DLBCL); Breakthrough Therapy designation to an antibody-drug conjugate for bladder cancer; and a double Fast...
Searching for Evidence-Based Reassurance Where None Could Be Found
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Quality of Life With Tisagenlecleucel Therapy for Relapsed or Refractory DLBCL
Adult patients with diffuse large B-cell lymphoma (DLBCL) whose disease was effectively treated with the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel showed sustained and clinically meaningful improvement in a variety of self-reported quality-of-life measures, according to...
Long-Term Outcomes With PD-1 Inhibitor Treatment and Response to Retreatment in Advanced Melanoma
In a single-center study reported in the Journal of Clinical Oncology, Allison Betof Warner, MD, PhD, and colleagues found that approximately three-quarters of patients with advanced melanoma achieving a complete response on programmed cell death protein 1 (PD-1) inhibitor therapy were alive...
Neoadjuvant Cisplatin for BRCA-Mutation Carriers: Pruning the Dead Branches
At the 2019 San Antonio Breast Cancer Symposium, Nadine Tung, MD, of Beth Israel Deaconess Medical Center, presented a multisite study called INFORM, run by the Translational Breast Cancer Research Consortium.1 It compared single-agent cisplatin with a “classic” combination of doxorubicin and...
Postmenopausal Estrogen and Risk of Breast Cancer: What Is the Real Story?
I am responding to an article in the January 25, 2020, issue of The ASCO Post on the conclusion of the 19-year follow-up on the Women’s Health Initiative (WHI) presented by Rowan T. Chlebowski, MD, PhD, at the 2019 San Antonio Breast Cancer Symposium: Postmenopausal estrogen administration does not ...
Using Machine Learning to Prompt Serious Illness Conversations
Despite research showing that among patients with cancer, early advance care planning conversations lead to care that is in alliance with patients’ goals and wishes, especially at the end of life,1 most patients die without having discussions about their treatment goals and end-of-life preferences ...
Strong Activity Shown for Lisocabtagene Maraleucel CAR T-Cell Therapy in Aggressive Large B-Cell Lymphoma
Another CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be poised to enter the marketplace for aggressive relapsed or refractory large B-cell lymphoma, based on a high rate of rapid and durable complete responses achieved with lisocabtagene maraleucel. The phase I TRANSCEND NHL...
Poster to Bedside: Geriatric Oncology Research Updates From 2019 ASCO Annual Meeting
Functional status impairment, limited mobility, comorbidities, polypharmacy, and other aging-related manifestations are common in older individuals. These conditions complicate the oncologic management of older adults, who are underrepresented in clinical trials, even though they form the majority ...
Pembrolizumab for BCG-Unresponsive, High-Risk Non–Muscle Invasive Bladder Cancer
On January 8, 2020, pembrolizumab was approved for treatment of patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.1,2...
Data From Colorectal Cancer Cohorts of TAPUR Study Presented
Positive findings from three Targeted Agent and Profiling Utilization Registry (TAPUR) study cohorts on the potential benefit of molecularly targeted drugs in patients with advanced colorectal cancer were presented at the 2020 Gastrointestinal Cancers Symposium.1-3 The TAPUR study is the first...
Highlights From ASH 2019 Included New Data in Leukemia, Lymphoma, and Multiple Myeloma
The ASH 2019 Annual Meeting & Exposition featured countless important sessions and lectures. It would be impossible to attend all the symposia, oral presentations, poster presentations, and special events. Below, we have selected some presentation highlights to supplement our coverage of the...
Pivotal Trial Evaluates Second-Generation BTK Inhibitor Alone and in Combination With Obinutuzumab for First-Line Treatment of CLL
The second-generation Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib, alone, or in combination with obinutuzumab significantly improved progression-free survival compared with a standard combination of obinutuzumab/chlorambucil in treatment-naive patients with chronic lympocytic leukemia...
Bruton’s Tyrosine Kinase Inhibitor Yields High Overall Response Rates in del(17p) CLL and SLL
In findings of the SEQUOIA trial and updated results of the AU-003 trial,1,2 zanubrutinib, a Bruton’s tyrosine inhibitor (BTK), was shown to produce high overall response rates for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), even in the presence of...
Next-Generation BCMA-Targeted CAR T-Cell Therapies for Relapsed or Refractory Multiple Myeloma Explored in Early-Phase Trials
Two novel dual-target chimeric antigen receptor (CAR) T-cell strategies are yielding early and durable responses for patients with relapsed or refractory multiple myeloma, as well as potentially less cytokine-release syndrome and neurotoxicity compared with first-generation CAR T-cell products,...
Combination Brentuximab Vedotin, Nivolumab Explored in First-Line, Salvage Therapies for Patients With Hodgkin Lymphoma
Two separate studies are investigating brentuximab vedotin plus nivolumab combination therapy for adults with Hodgkin lymphoma: one as first-line therapy and another as salvage therapy for relapsed/refractory classic disease, according to data presented at the 2019 Annual Meeting & Exposition...
Bispecific Antibody Shows Activity in Post–CAR T-Cell Therapy for Non-Hodgkin Lymphoma
Mosunetuzumab, an investigational bispecific antibody, demonstrated activity in preliminary studies of patients with non-Hodgkin lymphoma (NHL), including those who are refractory to or relapsed after third-line chimeric antigen receptor (CAR) T-cell therapy. With further study, mosunetuzumab,...
Expert Point of View: Howard J. Weinstein, MD, and Robert A. Brodsky, MD
Commenting on the Children’s Oncology Group AALL1331 study, Howard J. Weinstein, MD, Chief of Pediatric HematologyOncology at Massachusetts General Hospital for Children and Harvard Medical School in Boston, said: “These are very promising results for children, adolescents, and young adults who...
Blinatumomab Post-reinduction Consolidation Improves Event-Free, Overall Survival vs Chemotherapy in Young Patients With B-Cell ALL
Among children, adolescents, and young adults with B-cell acute lymphoblastic leukemia (ALL), the bispecific T-cell engager blinatumomab improved event-free survival and overall survival, compared with standard chemotherapy, as post-reinduction consolidation therapy at first relapse prior to...
Will Bispecific Antibodies Compete With CAR T-Cell Therapy in Lymphoma?
Are second-generation bispecific antibodies the next big thing in lymphoma? Studies of these drugs were among the highlights of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition. Years ago, the bispecific T-cell engager blinatumomab validated the concept of bispecific...
Conference Highlights From the 2019 American Society of Hematology Annual Meeting & Exposition
More than 25,000 specialists in hematology from over 115 countries attended the 61st American Society of Hematology (ASH) Annual Meeting & Exposition held last December in Orlando. The conference featured a stunning array of 4,900 abstracts with impressive new data in the treatment of multiple...
Hannah L. Rush, MBChB, on Prostate Cancer: Comparing Quality of Life in Patients Receiving Docetaxel or Abiraterone
Hannah L. Rush, MBChB, of the Clinical Trials Unit at University College London, discusses an analysis of the STAMPEDE trial, which showed that patients treated with abiraterone had higher scores in global quality of life as well as in the physical, social, and role function domains and lower...
Neeraj Agarwal, MD, on Castration-Resistant Prostate Cancer: Results From the COSMIC-021 Study of Cabozantinib and Atezolizumab
Neeraj Agarwal, MD, of the University of Utah Huntsman Cancer Institute, discusses trial findings that showed the combination of cabozantinib and atezolizumab had a tolerable safety profile and showed activity in men with metastatic disease. Further evaluation of cabozantinib and atezolizumab is...
No Improved Pathologic Complete Response With Atezolizumab in Early Triple-Negative Breast Cancer
The addition of the checkpoint inhibitor atezolizumab to chemotherapy with carboplatin and nab-paclitaxel failed to significantly improve pathologic complete response rates compared with chemotherapy alone in patients with early high-risk, locally advanced triple-negative breast cancer. According...
Proteomic Analysis of Endometrial Cancer
A comprehensive molecular study of endometrial cancer published by Dou et al in Cell has further defined the contributions of key genes and proteins to the disease. The overview suggests new treatment approaches that could be tailored for each patient, as well as potential biologic targets for...
HSD3B1 Genotype and Its Effect on Castration Resistance and Overall Survival in Prostate Cancer
As reported in JAMA Oncology, Nima Sharifi, MD, and colleagues have found that the adrenal-permissive HSD3B1 genotype is associated with earlier onset of castration resistance and poorer overall survival in men with low-volume metastatic prostate cancer. As noted by the investigators, the...
Osimertinib Plus Savolitinib for EGFR-Mutated, MET-Amplified NSCLC After Disease Progression on EGFR Tyrosine Kinase Inhibitors
As reported in The Lancet Oncology, Lecia V. Sequist, MD, and colleagues have found activity and an acceptable risk-benefit profile with the combination of the third-generation EGFR tyrosine kinase inhibitor osimertinib and the MET tyrosine kinase inhibitor savolitinib in patients with EGFR...
States With Highest Rates of Cutaneous Melanoma Due to Ultraviolet Exposure
A new study found a wide state-by-state variation in rates of melanoma caused by ultraviolet (UV) exposure, with highest rates in several states on the east and west coasts (including Hawaii), but also a few landlocked states (including Utah, Vermont, and Minnesota). The report, published by Islami ...
Expert Point of View: Andrea Wang-Gillam, MD, PhD
Andrea Wang-Gillam, MD, PhD, Clinical Director of the GI Oncology Program and Director of Developmental Therapeutics at Washington University in St. Louis, was the invited discussant of SEQUOIA and HALO 109-301. She tried to make sense of the two negative studies of pegylated agents in advanced...
Two Novel Pegylated Agents Fail in Metastatic Pancreatic Cancer
Two novel treatments once thought to hold promise in the treatment of metastatic pancreatic cancer have not proved to be effective in phase III trials, investigators reported at the 2020 Gastrointestinal Cancers Symposium. When combined with standard chemotherapy, a pegylated form of human...
Cervical Cancer Recurrence: Open vs Minimally Invasive Radical Hysterectomy
A multi-institutional retrospective study reported in the Journal of Clinical Oncology by Shitanshu Uppal, MBBS, and colleagues showed that minimally invasive radical hysterectomy was associated with a higher risk of disease recurrence vs open abdominal hysterectomy in women undergoing surgery for...
Perioperative Chemotherapy With or Without Cetuximab in Patients With Resectable Colorectal Cancer Liver Metastases
As reported in The Lancet Oncology by Bridgewater et al, the phase III New EPOC trial has shown that the addition of perioperative cetuximab to chemotherapy was associated with significantly poorer overall survival in patients with KRAS wild-type resectable colorectal cancer liver metastases. An...
Addition of Pembrolizumab to Neoadjuvant Chemotherapy in Early-Stage HER2-Negative Breast Cancer
As reported in JAMA Oncology by Rita Nanda, MD, and colleagues, findings from the ongoing phase II I-SPY 2 trial indicated that the addition of pembrolizumab to standard neoadjuvant chemotherapy improved pathologic complete response rates in patients with high-risk stage II/III HER2-negative breast ...
